CSL
Update in progressCSL.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
CSL Limited develops, manufactures, markets, and distributes biopharmaceuticals and vaccines worldwide, including Australia, the US, Germany, the UK, Switzerland, China, and Hong Kong. It operates in three segments: CSL Behring (plasma products, gene therapies, and biologics for immunology, hematology, cardiovascular/metabolic, respiratory, and transplant areas); Seqirus (influenza products and pandemic services to governments); and Vifor (iron deficiency and nephrology products). It licenses CSL IP. Founded 1916; based in Melbourne.
Company score
- Sentiment
- 0.07
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.07
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.43
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!